In Brief
Refine Search
Pharmaceutical
UK pharma major GSK today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for GSK5764227 (GSK’227), its B7-H3-targeted antibody-drug conjugate (ADC) being evaluated for the treatment of adult patients with relapsed or refractory osteosarcoma (bone cancer) who have progressed on at least two prior lines of therapy. 7 January 2025
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Pharmaceutical
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Pharmaceutical
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
Pharmaceutical
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Pharmaceutical
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
Pharmaceutical
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Pharmaceutical
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Pharmaceutical
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Pharmaceutical
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Pharmaceutical
Spanish plasma-derived medicines company Grifols announced with the Andorran government the cancellation of the immunology research center planned for the parish of Ordino. 29 July 2024
Pharmaceutical
Pharma giant Novartis has announced a strategic review of its listed entity in India. 19 February 2024
Pharmaceutical
UK pharma major AstraZeneca’s shares were up 2.7% at 10,094 pence Friday, after it revealed that its Tagrisso (osimertinib) with the addition of chemotherapy has been approved in the USA for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). 19 February 2024
Pharmaceutical
Autoimmune diseases specialist Aurinia Pharmaceuticals lost 24% of its market value on Thursday after presenting an update on the firm’s future. 16 February 2024
Pharmaceutical
US RNAi therapeutics company Alnylam Pharmaceuticals took a hefty 10% hit in the stock market on Thursday. 16 February 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for Augtyro (repotrectinib). 16 February 2024
Pharmaceutical
San Diego, USA-based precision oncology company Erasca announced two clinical trial collaboration and supply agreements (CTCSAs) with Swiss pharma giant Novartis for the MEK inhibitor Mekinist (trametinib). 15 February 2024
Pharmaceutical
US biopharma Merrimack Pharmaceuticals has revealed plans to dissolve and hand out cash to shareholders from a newly-announced milestone payment that the company is to receive. 15 February 2024
Pharmaceutical
Cathal Friel, co-founder, substantial shareholder, and currently non-executive chairman of London-listed Poolbeg Pharma, is assuming the role of executive chairman at the company effective immediately. 15 February 2024
Pharmaceutical
Today, the US Food and Drug Administration approved Aurlumyn (iloprost) injection to treat severe frostbite in adults to reduce the risk of finger or toe amputation. 14 February 2024
Pharmaceutical
Spanish plasma-derived products specialist Grifols has announced positive, top-line Phase III data for BT524, a fibrinogen concentrate being studied to treat patients with acquired fibrinogen deficiency, a bleeding disorder. 14 February 2024
Pharmaceutical
Shares in AN2 Therapeutics, a US biopharma focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, closed 74% lower on Monday. 14 February 2024
Pharmaceutical
US oncology company G1 Therapeutics was hoping for a positive interim analysis in its pivotal Phase III of trilaciclib alongside gemcitabine and carboplatin for the first-line treatment of metastatic triple negative breast cancer (mTNBC). 14 February 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has approved Onivyde (irinotecan liposome), from French drugmaker, in combination with oxaliplatin, fluorouracil, and leucovorin (NALIRIFOX regime), for the first-line treatment of metastatic pancreatic adenocarcinoma (mPDAC). 14 February 2024
Pharmaceutical
US trade group Pharmaceutical Research and Manufacturers of America (PhRMA) has made clear its opposition to the drug price-setting provisions in the Biden administration’s Inflation Reduction Act (IRA). 14 February 2024
Pharmaceutical
US AI-enabled drug discoverer VantAI has entered into a strategic collaboration with pharma major Bristol Myers Squibb to discover new molecular glues for therapeutic targets of interest. 14 February 2024
Pharmaceutical
Novo Nordisk has come out on top in two cases in Florida courts relating to its weight loss drug Wegovy (semaglutide). 13 February 2024
Pharmaceutical
KalVista Pharmaceuticals shares, which closed Monday at $16.04, were recently up 37% to $22 in pre-market activity, but fell back almost 13% to $14.01 by late morning today, after it released new research data. 13 February 2024
Pharmaceutical
Japanese pharma major Takeda has announced that the US Food and Drug Administration (FDA) has approved Eohilia (budesonide oral suspension), the first and only FDA-approved oral therapy for people 11 years and older with eosinophilic esophagitis (EoE). 13 February 2024
Pharmaceutical
Shares of Japanese drugmaker Otsuka Pharmaceutical fell more than 5% to 5,359 yen today, as it released top line results of the Phase III clinical trial of AVP-786 in the treatment of agitation associated with dementia due to Alzheimer's disease. 13 February 2024
Pharmaceutical
The Yellow Card Biobank, a pilot launched by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and Genomics England, is to start investigating a group of medicines used to prevent strokes known as direct oral anticoagulants (DOACs). 13 February 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze